New Discoveries for Drug & Nutraceuticals: Biopharm/Orthopharm, mRNA Vaccines, Protein-Like/Fructan-Like/Long-chain Fatty Acid Polymers (PLPs, FLPs, LFPs), and theoretical "Rotary" Biozymes as a Cardio Purge and Textile Cleanse.
By D. A. Flores
As we gather the latest reports for sequencing genomes like the human variety is clocked at 10 mins (e. g. MGI Tech's sequencer model, the DNBSEQ-T7+). We assume this hi-throughput is not only true for time but also capacity in samples handling. This will be employed with what is referred to in Bioinformatics New Generation Sequencing (NGS) together with Data Analysis.
These protocols would have the task or capacity to assemble genomes together, identify mutations and including classifying mutant pathogen strains and with high precision. This can lead to further work for vaccine development including tropical countries and can even also be applied for ensuring food safety.
It has been reported that organizations like the Center for Disease Control (CDC) will employ capacity and data analysis collaboration to track and with analysis respond to regulate public health.
At Skye Blue we are still negotiating use of our exclusive and proprietary reagent analyte, a tagged detergent dye chromophoric molecule to separate and quantify/ID the protein analytes like for biopharma and further down the road sequencing with extreme speed, accuracy and capacity, proteins utilizable for drug discovery with biopharmaceutical applications, ortho-chemical drug design or for mRNA-based vaccines and more conventional type vaccines.
There are new protein-like polymers (PLPs), a new drug material polymer which arrived just awhile ago and "SkyeBlue" thinks possibly, if its molecular length/weight (rod-like conformation) is suited, for an electrophorescing separation column for analysis using the same detergent-dye tagged protocol, and further down the road, other types of PLPs of different structures and applications as in biopolymeric molecular assemblies. Take for e. g., based on nutraceuticals, for designing the candidate polymeric drug "designer" biomaterial for a target "receptor" metabolite application, as in health and nutrition.
Two e. g. currently to be used possibly for clinical treatment by "SkyeBlue" are SCI related conditions like rheumatoid arthritis (RA) (still speculative) and other called heart attack or myocardial infarction (MI) (on its way to pre-clinical trials) involving the inflammatory response and pharma designed as globular hydrophobic cored and side-chained with bioactive peptide designed strands that act directly on the domains of the so-called Kelch protein otherwise reacting with and deactivating Nrf2, which down the road, results in further steps including activation of the inflammatory response and so forth, which constitutes the aetiology of the RA condition (viz. including erosion of the cartillage and bone of the human extremeties). In the case of RA the culprit is so-called reactive oxygen species (ROS)(superoxide and H2O2) produced by the enzyme called NOX4 (NADPH oxidase 4); apparently the NOX4 factor is not clearly established yet by the aetiology with RA. Perhaps the Nrf2 story and its inflammatory-related aetiology is more of a drug target as is the case in MI.
As a footnote, here the conception of polymer extension to impact on drug delivery whether it be a globular protein affecting the inflammatory condition like our PLP-specific drug (with Nrf2) and further speculation of fructan as a sugar of greater length or MW as a potential potent nutraceutical and another fact of the lower gut being a potent immunological-related organ of significance to SCI and with its absorption yet through and into the gut lining to act there in some way is our hypothesis. And yet another e. g. called conjugated or connected fatty acids called conjugated linoleic acid (CLA) of known nutraceutical potency is also a possible theory for clinical drug discovery and delivery.
Yet another area of research opening up as we speak is peptide research regards the leader sequences, the typical peptide length or its superelongation and the rate of uptake of its amino acids and incorporation into microbial cell biomass protein in rumen digestive processing in large ruminant livestock for meat and dairy with respect to the membrane bound transport systems for these peptides.
Preparation from feed manufacturing will be dependent on clean bioreactor processing to bulk tonnage capacity using gene edited yeast hosts that have been processed as DNA-free biomass or non-GMO labelled protein supplements and that have been treated to slow their breakdown as biomass and protein to facilitate uptake into utilizing microbial cells with digestion in the rumen stomach digestive process. Also, the amino acid (AA) composition of superelongated peptides will depend on their limitation in microbial protein synthesis which will in turn be reflected on the essential (to the host) AA profile of the resulting nutrient biomass from microbial flows, in addition to the escape component untouched by microbial digestion from dietary sourced feed protein.
Polymer chemistry might yet see new possibilities in this new area outlined above, by extension to other fields, like nutraceutical developments as we predict. And it appears that nutraceuticals, as our specialty, thus far, used to mine the [LMW]-proteome for pharma, is still to ff. at "SkyeBlue".
Proteomics research might still uncover new structure-functional relationships for enzymes (or biozymes) as symmetrically circular, viz. cf. to a rotary wheel whole units have a unique tertiary (3rd degree structural) mechanism that literally passes around substrates from unit to unit for processing for applications as 'molecular scrubbers' making faster and more efficient biozymes as detergents for textiles and drug scrubbers against plaques for cardiac health.
E. g. s. are Oxidative Biozymes, perhaps a futuristic detergent for Outerspace to wash apparel and suits as an ultra-fine and fast cleaner.
E. g. s. are Oxidative Biozymes, for cleaning out plaques in arteries addressing the exact mechanism that holds cells together, i. e. connective cell tissue to be identified that holds plaque-bearing cells and further addressing oxidation of cholesterol on the arterial wall.
Theoretical considerations include "patterning" original findings of a folate-dependent enzyme and its underlying tertiary structural mechanistic details involving passing one substrate from one active site to another in a "rotary" fashion, which in this case is oxidative active site design and revealing mechanistic kinetics to formulate the whole mechanism involved.
It is our best guess that rather than more imaginative "prosthetic" mechanisms between active sites that a "close-call diffusive" mechanism holds for our Rotary Biozyme model that can pass products and intermediates between tertiary subunits like a "molecular scrubber" on its active surface for much more efficient action per sq. area per unit time.
New molecular mechanisms evolve in drug research and discovery and the "PLPs" and "Rotary Biozymes" are just the beginning we believe that spells out new breakthroughs for bio/technology.
We should continue with one last other e. g. in a theory called "Protein-Energy Theory" in Rumen Protein Nutrition in livestock and the role in it of bioactive peptides as "cofactors" chaperoned with protein synthesizing machinery enzymes acting in rumen microbial cells for synthesis of microbial cell protein (MCP) in rumen biomass over and above the escape of the rest of dietary protein going through that part of the gut.
[Forwarded Salutations] Regards to all your colleagues and friends,
The Owner and Principal
Skye Blue (SB) Press Corporation
Poco BC Canada V3B 1G3
+1 (236) 983-6419
skyebluepublications@aim.com
W. hum-molgen.org (DE)(EU)
W. sbinternet.ca (CA)(US)
W. skyebluepresscorporation.com (CA)
W. skyebluepresscorporation.ca (CA)
W. skyebluedoitfaxitbiz.ca (CA)(US)
(c) 2025-2059. Skye Blue Press Corporation. Port Coquitlam, BC V3B 1G3 Canada.